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in Murine Liver After Ornithine Transcarbamylase
Gene Correction
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Abstract
Recombinant adeno-associated viruses (rAAVs) have been tested in humans and other large mammals without
adverse events. However, one study of mucopolysaccharidosis VII correction in mice showed repeated inte-
gration of rAAV in cells from hepatocellular carcinoma (HCC) in the Dlk1–Dio3 locus, suggesting possible
insertional mutagenesis. In contrast, another study found no association of rAAV integration with HCC, raising
questions about the generality of associations between liver transformation and integration at Dlk1–Dio3. Here
we report that in rAAV-treated ornithine transcarbamylase (Otc)–deficient mice, four examples of integration
sites in Dlk1–Dio3 could be detected in specimens from liver nodule/tumors, confirming previous studies of
rAAV integration in the Dlk1–Dio3 locus in the setting of another murine model of metabolic disease. In one case,
the integrated vector was verified to be present at about one copy per cell, consistent with clonal expansion.
Another verified integration site in liver nodule/tumor tissue near the Tax1bp1 gene was also detected at about
one copy per cell. The Dlk1–Dio3 region has also been implicated in human HCC and so warrants careful
monitoring in ongoing human clinical trials with rAAV vectors.
Introduction
Previous studies of hepatocellular carcinoma (HCC) inmice after exposure to recombinant adeno-associated vi-
rus (rAAV) vectors have reached different conclusions re-
garding possible insertional mutagenesis. Donsante et al.
(2007), after rAAV transduction of normal mice, found four
examples of integration sites in HCC tumors in the delta-like
homologue 1–deiodinase type 3 (Dlk1–Dio3) region, which
contains a large collection of genes encoding microRNAs and
snoRNAs on chromosome 12 (Donsante et al., 2007). Quanti-
fication of vector copy number in transformed cells showed
that these integration sites reached an abundance of up to 28%
of diploid genomes. Because murine liver cells may have
higher ploidy than typical diploid cells, and tumor cells may
be mixed with untransformed cells, this was proposed to be
consistent with insertional activation, in which every trans-
formed cell is derived from a single clone expected to contain
the activating integration event. However, a subsequent
study of hemophilia gene therapy in mice showed no eleva-
tion in HCC rates after rAAV exposure, and genome-wide
surveys by pyrosequencing showed no integration sites in the
Dlk1–Dio3 locus in tumor samples (Li et al., 2011). Recently, a
study in which rAAV was deliberately targeted to the Dlk1–
Dio3 locus resulted in HCC (Wang et al., 2012). Exposure to
AAV or rAAV has not been associated with transformation in
large animal models or humans, leaving the possible role of
rAAV in transformation uncertain. rAAV-based vectors are
presently in use in human clinical trials to treat cystic fibrosis,
a-1 anti-trypsin deficiency, Parkinson’s disease, Batten’s dis-
ease, muscular dystrophy, Leber’s congenital amaurosis, and
hemophilia B (Flotte et al., 2004; Mandel et al., 2006; Kaplitt
et al., 2007; Maguire et al., 2008; Worgall et al., 2008; Nathwani
et al., 2011), highlighting the importance of further under-
standing possible genotoxicity by rAAV.
We therefore studied rAAV integration sites in liver
nodules or tumors arising during a preclinical study of liver
gene therapy for ornithine transcarbamylase (Otc) deficiency
(OTCD) in mice using intraportally delivered rAAV serotype
2, 7, and 8 vectors (Bell et al., 2006). As in many other studies
of insertional activation of oncogenes in human and mice
(Hacein-Bey-Abina et al., 2003; Kohn et al., 2003; Donsante
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et al., 2007), we reasoned that recurrent vector integration
events in a single locus in tumor tissue would indicate a
potential contribution of insertional activation to transfor-
mation. The study in OTCD mice attempted to characterize
the unexpected observation of liver nodules in long-term
surviving vector-treated mice. The article of Bell et al. (2006)
described the incidence and histological analysis of nodules
and in a subset of tissues, also vector abundance. The strain
of mice used in these studies has a high background of
spontaneous nodules and HCC, making it difficult to ascribe
a vector to tumor formation. The key findings were a sta-
tistically significant increase and nodules and HCC of vector-
treated animals over untreated animals only when the vector
expressed lacZ. There was no increase in nodules/HCC
when the vector expressed OTC; in fact, a metabolic correc-
tion with gene therapy may have diminished background
tumors, consistent with the recent observation that OTCD is
associated with an increased risk of HCC (Wilson et al.,
2012). Thus, we sought to investigate possible insertional
activation by characterizing the distributions of integrated
rAAV genomes in nodules/tumors and adjacent normal
tissues from the study of Bell et al. (2006), using deep se-
quencing of junctions between rAAV and flanking host
DNA, with particular focus on the Dlk1–Dio3 locus.
Materials and Methods
Isolation of total cellular DNAs from liver tumor
and adjacent normal tissues
The adjacent normal liver and tumor/nodule DNA sam-
ples were isolated from samples according to Bell et al.
(2006). Briefly, the tissue samples were collected from the
Otc-deficient male mice at 12 months after intraportal injec-
tion with rAAV2, 7, and 8 vectors expressing either the
mOTC or the LacZ gene driven by the human thyroid
hormone-binding globulin (TBG) promoter. The genetic
background of those mice was B6C3F1, which was bred by
crossing C57BL/6 with C3H mice. Frozen liver and tumor
tissue was homogenized in a lysis buffer using TissueLyser II
(Qiagen, Valencia, CA) and total cellular DNA was extracted
by the Qiagen DNEasy kit (Qiagen).
DNA sequencing
rAAV inverted terminal repeat (ITR)–host genomic DNA
(gDNA) junction libraries were prepared using standard
methods, which are described in the Supplementary Meth-
ods section (Supplementary Data are available online at
www.liebertonline.com/hum). The purified libraries of
rAAV ITR–host gDNA junction fragments were sequenced
by a Genome Sequencer FLX pyrosequencer (Roche/454 Life
Sciences, Branford, CT) at the University of Pennsylvania
DNA Sequencing Facility.
Genome-wide analysis of rAAV integration sites
Pyrosequencing reads (stored and manipulated in a
MySQL database) were first decoded using DNA barcodes,
which separated the sequence reads by mouse and tissue of
origin. Reads were then aligned against the linker and rAAV
ITR primers using the Crossmatch program and subse-
quently trimmed. Reads passing the trimming criteria were
aligned against vector sequences using BLAT (stepSize = 5;
tileSize = 10). BLAT hits were processed as described by Li
et al. (2011) to distinguish concatemers from authentic inte-
gration events. Sequences carrying authentic integration site
junctions were aligned to the mouse genome (UCSC freeze
mm8) using BLAT. To call a read as an authentic rAAV in-
tegration site, 15 bases of ITR DNA were required to be
present between the primer site and the flanking mouse
DNA to exclude reads resulting from mispriming on the
mouse genome, the match to the mouse genome was re-
quired to start within three bases of the ITR end, and the
match to the mouse genome was required to be 70% of
FIG. 1. Flow chart summarizing the analysis of rAAV
vector integration site distributions. Initially, 10 samples
were selected from the study of Bell et al. (2006), consisting of
paired tumor and normal liver DNA specimens from five
mice containing liver nodules or tumors after exposure to
rAAV. These were used to generate 10 integration site li-
braries, one per specimen, that were sequenced using the
454/Roche pyrosequencing method, yielding 1,580 unique
integration site positions. Of these, 11 were selected for
verification because of possible involvement in transforma-
tion based on high relative abundance (n = 8), proximity to
cancer-related genes (n = 3), or location in the Dlk1–Dio3 lo-
cus (n = 5), which was previously suggested to be associated
with rAAV integration in hepatocellular carcinoma. Note
that the sum of the numbers above is greater than 11 because
some sites were chosen based on more than one criteria (see
Table 1). Of the 11 integration sites, 9 could be validated by
PCR amplification, cloning in bacterial plasmids, and DNA
sequencing. Of these, two out of nine were present at *1
copy per cell (Table 1). rAAV, recombinant adeno-associated
virus; PCR, polymerase chain reaction.
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sequence size with 98% identity. Integration sites in the mouse
genome were analyzed as described in previous publications
(Berry et al., 2006; Li et al., 2011). A detailed explanation of
genomic heatmaps can be found in Ocwieja et al.’s (2011)
supplementary text ‘‘Guide to Interpreting Genomic Heat
Maps Summarizing Integration Site Distributions.’’ Cancer-
related genes were identified with a collection of cancer-related
gene lists from seven different sources. Integration site data
sets and oligonucleotides used for analysis are listed in Sup-
plementary Tables S1 and S2. DNA sequences have been
deposited at Genebank under the accession numbers JS187093 -
JS564611, library accession LIBGSS_038841.
Browsing rAAV integration sites on the mouse genome
The integration sites studied here can be viewed using the
UCSC genome browser.
Results and Discussion
We chose to study the five mice from the Bell et al.’s (2006)
report with the highest numbers of vector copies in tumors
based on polymerase chain reaction (PCR) analyses, because
these were more likely to be caused by insertional activation
and harbor monoclonal integration sites (Fig. 1). Ligation-
mediated PCR and pyrosequencing of rAAV integration sites
(Li et al., 2011) yielded a total of 999,442 sequence reads.
Dereplication yielded 608 unique integration sites from the
tumor/nodule samples and 972 unique integration sites from
the adjacent normal liver controls (Fig. 1; Supplementary
Methods and Tables S1 and S2).
For each of the five mice studied, integration sites were
compared between the liver nodules and flanking normal
tissue (Supplementary Table S2). The relative abundance of
reads provided a first indication of the abundance of cells
hosting vectors at these locations, though this estimate is
considerably complicated by biases in the recovery process
(discussed further below). The positions of all integration
sites on the mouse genome can be viewed along with user-
configurable annotation as described in the Materials and
Methods section. The distribution of integration sites was
then analyzed in detail (Fig. 2). Figure 2 shows that inte-
gration sites are distributed along the length of each chro-
mosome, without obvious clustering in hotspots. Global
distributions of rAAV integration sites were analyzed rela-
tive to genomic features, and were generally as in previ-
ous studies. Supplementary Figure S1 presents a statistical
FIG. 2. Distribution of rAAV integration sites in liver nodule/tumor and flanking normal tissue for the five mice studied.
For each mouse, the chromosomes are shown numbered sequentially in circular ideograms (outermost ring). Progressing
inward, relative gene density is shown by the red bars, positions of integration sites in normal liver is shown by the green
dots, and integration sites in nodule/tumor samples is shown by the brown dots.
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analysis for integration site distributions relative to many
types of genomic features. Integration sites usually showed
a slight enrichment in gene-dense regions and near gene 5¢
ends compared with computational random distributions.
Features associated with gene 5¢ ends such as CpG islands
were also enriched, though with a considerable sample-to-
sample variation. Analysis of the integration site distri-
butions relative to the AAV serotypes suggested some
possible differences, though the power was limited because
of the modest number of mice studied (Supplementary
Fig. S1).
We next sought to quantify the absolute abundance of
integration sites that were candidates for involvement in
insertional activation as an indication of expansion of vector-
marked cell clones. Recovery of rAAV–host DNA junctions is
complicated by the palindromic structure of the ITR se-
quences at each end of the rAAV genome, because the DNA
secondary structure can interfere with PCR amplification
and DNA sequencing (Supplementary Fig. S2). Thus, the
population of integration sites studied may be incomplete,
and quantifying vector abundance by counting sequence
reads provides only an initial estimate.
Integration sites were selected for verification based on
three criteria: relative abundance of sequence reads, prox-
imity to cancer-associated genes, and proximity to the Dlk1–
Dio3 locus (Table 1; note that some sites were chosen based
on more than one criteria). Eleven integration sites that met
these criteria were selected from 1,580 unique rAAV inte-
gration sites revealed by pyrosequencing, 10 from tumor/
nodule (i.e., 276TM, 315TM, and 506TM, respectively), and 1
Dlk1–Dio3 site from flanking normal tissue (i.e., 276LV)
(Table 1). These four samples had sufficient DNA for follow-
up analysis. We first attempted to reamplify the integration
sites using targeted PCR primers, followed by cloning
products into bacterial plasmids and sequencing by the
Sanger method (Supplementary Methods). Extensive efforts
were made for each site, involving amplification attempts
with multiple primer pairs. A total of 9 sites in 3 samples (i.e.,
276TM, 276LV, and 506TM) were verified out of the 11 at-
tempted (Table 1). A total of five sites in the Dlk1–Dio3 region
could be verified, one from normal tissue and four from
tumor-nodule tissue, thus showing a trend toward enrich-
ment in the tumor-nodule samples ( p= 0.076; Fisher’s exact
test).
Quantitative PCR was then conducted for these three
samples, each of which has 2–3 copies of vector genome per
cell as detected by a vector-specific primer/probe set, to
quantify the number of integrants per cell in tumor and
normal tissues at the confirmed loci (Supplementary Table S2
and Supplementary Methods). A total of 48 different am-
plicons were tested over the 9 sites for efficiency of amplifi-
cation. Because of the secondary structure, several primers
were tested near the edge of the ITR for each site. This al-
lowed two integration sites to be documented as present at
*1 copy per cell in the tumor samples by quantitative PCR,
as is required in the insertional activation model (Supple-
mentary Table S3 and Supplementary Fig. S3), though we
note that potential polyploidy in liver cells complicates this
picture. It is unknown whether the lower numbers for the
remainder of the sites were because of authentic low-level
abundance of these sequences or unsolved problems in am-
plification through the ITR.
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One of the sites that were confirmed at *1 copy per cell
resided in the Dlk1–Dio3 locus in the Rtl1 gene. A total of five
integration sites were detected in the Dlk1–Dio3 locus, four
from the nodule/tumor samples and one in the normal liver
controls (Fig. 3 and Table 1). The rAAV ITR sequences were
partially rearranged in two out of six integration sites at
Dlk1–Dio3, as was often the case for rAAV integration sites.
The other integration site with a copy number near 1 per cell
was in the Tax1-binding protein 1 (Tax1bp1) gene, which
hosted two integration sites over the full data set (Fig. 3). The
Tax1bp1 gene has been implicated in suppressing inflam-
mation by negatively regulating NFjB.
In murine cancer models, insertional activation is often
used for discovery of cancer-associated genes—the finding of
monoclonal insertion sites in independent tumors near a
specific gene suggests direct involvement of that gene in
transformation. Here we found an additional example of
integration in the Dlk1–Dio3 region in a tumor/nodule
sample, reaching *1 copy per cell, consistent with the idea
that the insertion contributed to transformation. The level of
marking at Dlk1–Dio3 in the tumor/nodule sample here was
higher than that in the previous study (Donsante et al., 2007),
strengthening the case for insertional activation. Three ad-
ditional sites that are of unknown importance were also
found in nodule/tumor tissue in the Dlk1–Dio3 locus,
though for these we could not show high-level marking in
tumors. We also identified another gene with a monoclonal
integration event, Tax1bp1, which encodes a negative regu-
lator of NFjB and inflammatory pathways, and is a potential
negative regulator of cell growth (Verstrepen et al., 2011),
though for this gene we have not observed multiple inde-
pendent events suggestive of insertional activation. Com-
plicating the picture, large numbers of additional integration
sites were isolated from each of the tumors, and their origin
is unclear. One explanation is that these represent admixture
of untransformed cells. However, an alternative is that these
are from transformed cells of different origins, which would
imply that the cancers were probably of polyclonal origin,
since it seems unlikely that so many different integrants
would reside in the same cell. Unfortunately, tissue samples
were not available that would allow for follow-up analysis,
for example, by carrying out a detailed study of alterations in
gene expression in genes near sites of rAAV integration.
Data linking Dlk1–Dio3 integration events with liver
transformation must, nevertheless, be interpreted with some
caution. The mouse study, which was the subject of these
molecular analyses, was not designed to assess vector-
mediated carcinogenesis. In fact, there was a statistically
significant increase in tumors of animals treated with rAAV
expressing lacZ over a fairly high background of tumors in
non-vector-treated animals. However, treatment with rAAV-
expressing OTC did not increase tumor formation and, in
fact, may have diminished tumors. The paradox is that the
tissues that harbored Dlk1–Dios3 integrations came from
rAAV.OTC-treated animals (two nodules and one adjacent
normal liver). The very nature of these kinds of studies
makes it impossible to rule out that the rAAV integration
events marked cells that progressed to nodules or tumors for
reasons unrelated to integration. As reported in humans
(Wilson et al., 2012), the OTC mice may be predisposed to
HCC—chronic liver damage caused by accumulation of toxic
metabolites and inappropriate regulation of nucleotide pools
by elevated pyrimindine production, both of which are
characteristic of OTC and associated with liver cancer. This
in fact may explain why rAAV.OTC gene therapy could be
protective. In addition, if integration events are involved in
transformation, they are likely only one of multiple genetic
insults.
Since the initial report of Donsante et al. (2007), consider-
able new data have accumulated on the function of the Dlk1–
Dio3 region. The locus contains genes for *60 microRNAs
and multiple snoRNAs and is imprinted, and correct ex-
pression is functionally associated with stem cell plur-
ipotency (Stadtfeld et al., 2010). A recent study implicated a
stem-like expression pattern in the syntenic human region at
14q32.2 as diagnostic for poor survival in human HCC (Luk
FIG. 3. Integration sites of
rAAV in tumor/nodule sam-
ples at the (A) Dlk1–Dio3 and
(B) Tax1bp1 loci. Integration
sites are shown as bright
green vertical lines, and the
mouse of origin is shown to
the left. The integration site
positions reported by Don-
sante et al. (2007) are shown
in (A) by the blue-green lines.
The snoRNA annotation
(blue lines) was derived from
the annotation of the syntenic
region of the human genome,
and the miRNA annotation
(red lines) was from experi-
mental data in mice. All an-
notation was adapted from
tables at http://genome.ucsc
.edu/.
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et al., 2011). Furthermore, the Rian gene within the Dlk1–Dio3
locus was identified by transposon insertion screens as a
common integration site in murine HCC (Akagi et al., 2004;
Dupuy et al., 2009), and a targeted study showed that inte-
gration within this locus can be associated with HCC (Wang
et al., 2012). Thus, the role of rAAV integration in causing
tumors in the OTC model reported here is unclear, but adds
to the picture of sensitivity of the Dlk1–Dio3 locus in com-
bination with these other studies. These data, together with
previous studies, emphasize that potential rAAV genotoxi-
city associated with integration in this locus warrants
monitoring.
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